Home » Novartis: Oral MS Therapy Reduces Relapses
Novartis: Oral MS Therapy Reduces Relapses
Novartis AG said that initial results from a late-stage study showed that treatment with oral FTY720 significantly reduced relapses and disability progression in patients with multiple sclerosis compared to placebo.
RTTNews
RTTNews
Upcoming Events
-
07May
-
14May
-
30May